Angeja B G, Rundle A C, Gurwitz J H, Gore J M, Barron H V
Genentech Inc, South San Francisco, California, USA.
Am J Cardiol. 2001 Mar 1;87(5):627-30, A9. doi: 10.1016/s0002-9149(00)01441-7.
In a retrospective cohort of patients treated in community hospitals, tissue plasminogen activator (t-PA) was associated with decreased odds of in-hospital death or nonfatal stroke. However, the relative benefit was less evident in older patients and women, and some older subgroups did not benefit from treatment.
在一个对社区医院接受治疗的患者的回顾性队列研究中，组织型纤溶酶原激活剂（t-PA）与住院死亡或非致死性卒中几率降低相关。然而，这种相对获益在老年患者和女性中不太明显，并且一些老年亚组并未从治疗中获益。
